Deaggregation of In Vitro-Degranulated Human Platelets: Irreversibility of Aggregation May Be Agonist-Specific Rather Than Related to Secretion Per Se

Summary

Based on studies with thrombin, it has been proposed that human platelets exposed to strong release-inducing agents undergo irreversible aggregation and cannot be deaggregated without the use of proteolytic enzymes. We tested the hypothesis that irreversible human platelet aggregation occurs as a result of thrombin-specific platelet alterations rather than induction of the release reaction per se. Washed human platelets were exposed to either thrombin (THR) or the aminophospholipid N-(7-Nitro- 2,1,3-benzoxydiazol-4-yl) phosphatidylserine (NBD-PS) for 20 seconds. Both agents caused similarly extensive release of platelet dense- and α-granule contents. After neutralization of thrombin and NBD-PS, and addition of PGE₁ and apyrase, the platelets were sedimented, resuspended and incubated at 37° C with gentle agitation. Single, disc-shaped, degranulated platelets which were recovered in both systems were capable of aggregation in response to a second exposure to aggregating and release- inducing stimuli. Deaggregation was more rapid, more extensive, and more reproducible with NBD-PS- than with THR-degranulated platelets. Platelets exposed to thrombin for longer than 20 seconds showed a progressive loss of deaggregability which was not observed after prolonged incubation with NBD-PS. These findings do not support the concept that extensive secretion per se causes irreversible aggregation of human platelets. Instead it appears that formation of irreversible linkages between platelets involves the specific, time-dependent interaction of THR with platelets, released fibrinogen and possibly one or more other substances secreted from platelets.

Keywords

Irreversible platelet aggregation - Thrombin - NBD-phosphatidylserine

• References

• 1 Pareti FI, Capitano A, Mannucci L, Pontieelli C, Mannucci PM. Acquired platelet dysfunction due to the circulation of “exhausted” platelets. Am J Med 1980; 69: 235-240
• 2 Marker LA, Malpass TW, Branson HE, Hessel EA, Slichler SJ. Mechanism ot abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective (/-granule release. Blood 1980; 56: 824-834
• 3 Reimers H-J, Packham MA, Kinlough-Rathbone RL, Mustard JF. Effect of repeated treatment of rabbit platelets with low concentrations of thrombin on their function, metabolism and survival. Br J Haematol 1973; 25: 675-689
• 4 Kinlough-Rathbone RL, Mustard JE, Perry DW, Dejana E, Cazenave J-P, Packham MA, Harfenist EJ. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemostas 1983; 49: 162-167
• 5 Kinlough-Rathbone RE, Perry DW, Packham MA, Mustard JF. Deaggregation of human platelets aggregated bv thrombin. Thromb Haemostas 1985; 53: 42-44
• 6 Guccione MA, Kinlough-Rathbone RL, Perry DW, Packham MA, Harfenist EJ, Rand ML, Greenberg JP, Mustard JF. Effects of plasmin on rabbit platelets. Thromb Haemostas 1985; 53: 8-14
• 7 Martin IW, Joist JH, Bauman JE, LagunolT D. Activation of human platelets by N-substituted aminophospholipids. J Biol Chem 1985; 260: 2852-2856
• 8 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparations of suspensions of washed human platelets. Br J Haematol 1972; 22: 193-204
• 9 Molnar J, Lorand L. Studies on apyrases. Arch Biochem Biophys 1961; 93: 353-363
• 10 Pletscher AL. Metabolism, transfer and storage of 5-hydroxytrypt- amine in blood platelets. Br J Pharmacol Chemother 1968; 32: 1-16
• 11 Hawiger J, Perry DW, Timmons S. Prostacyclin inhibits mobilization of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature 1980; 283: 195-199
• 12 Harfenist EJ, Packham MA, Kinlough-Rathbone RL, Mustard JF. Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets and cause rapid deaggregation and dissociation of bound fibrinogen. J Lab Clin Med 1981; 97: 680-688
• 13 Plow EF, Marguerie GA. Participation of ADP in the binding of fibrinogen to thrombin stimulated platelets. Blood 1980; 56: 553-555
• 14 Joist JH. Fibrinopeptide A in the diagnosis and treatment of venous thrombosis and pulmonary embolism. Clin Lab Med 1984; 4: 1-18
• 15 Nahas L, Kamiguti AS, Barros M AR. Thrombin-like and factor X- activator components of Bothrops snake venoms. Thromb Haemostas 1979; 41: 314-328
• 16 White JG. Electronmicroscopic studies of platelet secretion. Progr Hemostas Thromb 1974; 2: 49-98
• 17 Nachman RL, Leung L LK. Complex formation of platelet membrane glycoproteins lib and Ilia with fibrinogen. J Clin Invest 1982; 69: 263-268
• 18 Jaffe EA, Leung L LK, Nachman RL, Levin RI, Mosher DF. Thrombospondin is the endogenous lectin of human platelets. Nature 1982; 295: 246-248
• 19 Ginsberg MH, Plow EF, Forsyth J. Fibronectin expression on the platelet surface occurs in concert with secretion. J Supramol Struct Cell Biochem 1981; 17: 91-98
• 20 Plow EF, McEver RP, Coller BS, Woods VL, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-727
• 21 Ruggeiro M, Lapetina EG. Sustained proteolysis is required for human platelet activation by thrombin. Thromb Res 1986; 42: 247-245
• 22 Wolff R, Plow EF, Ginsberg MH. Interaction of thrombospondin with resting and stimulated human platelets. J Biol Chem 1986; 261: 6840-6846
• 23 Tam SW, Fenton JW, Detwiler TC. Dissociation of thrombin from platelets by hirudin. Evidence for receptor processing. J Biol Chem 1979; 254: 8723-8725
• 24 Hallam TJ, Ruggles PA, Scrutton MC, Wallis RB. Desensitization in human and rabbit blood platelets. Thromb Haemostas 1982; 47: 278-284
• 25 Reimers H-J, Kinlough-Rathbone RL, Cazenave J-P, Senyi AF, Hirsh J, Packham MA, Mustard JF. In vitro and in vivo functions of thrombin-degranulated platelets. Thromb Haemostas 1976; 35: 151-166
• 26 Kaplan KL, Dauzier MJ, Rose S. ADP and epinephrine-induced release of platelet fibrinogen. Blood 1981; 58: 797-802
• 27 Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood 1978; 52: 453-466
• 28 Soria J, Soria C, Borg JY, Mirshahi M, Piguet H, Tron P, Fessard C, Caen JP. Platelet aggregation occurs in congenital afibrinogenaemia despite the absence of fibrinogen or its fragments in plasma and platelets, as demonstrated by immunoenzymology. Br J Haematol 1985; 60: 503-514
• 29 Kunicki TJ, Newman PJ, Amrani DL, Mosesson MW. Human platelet fibrinogen: Purification and hemostatic properties. Blood 1985; 66: 808-815
• 30 Pared FI, Capitano A, Mannucci PW. Acquired storage pool disease in patients with disseminated intravascular coagulation. Blood 1976; 48: 511-515
• 31 George JN, Pickett E BN, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on lesting and activated platelets and platelet membrane microparticles in normal subjects, and observations during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986; 78: 340-348